Trevi Therapeutics, Inc. Net Income
Trevi Therapeutics, Inc. (TRVI) reported Net Income of -$17.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$17.80M.
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$13.19M.
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$8.32M.
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$11.80M.
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$29.15M.
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$33.94M.
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$32.76M.
- Trevi Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2019 was -$26.05M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$17.80M 10-Q · filed 2026-08-06 | -$30.99M 10-Q · filed 2026-08-06 | -$39.31M derived: sum of 3 quarters · filed 2026-08-06 | -$51.11M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$13.19M 10-Q · filed 2026-05-05 | -$21.51M derived: sum of 2 quarters · filed 2026-05-05 | -$33.31M derived: sum of 3 quarters · filed 2026-05-05 | -$45.61M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$8.32M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$20.12M derived: sum of 2 quarters · filed 2026-04-21 | -$32.42M derived: sum of 3 quarters · filed 2026-08-06 | -$42.76M DEF 14A · filed 2026-04-21 | -$42.76M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$11.80M 10-Q · filed 2025-11-13 | -$24.10M derived: sum of 2 quarters · filed 2026-08-06 | -$34.44M 10-Q · filed 2025-11-13 | -$45.86M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$12.30M 10-Q · filed 2026-08-06 | -$22.64M 10-Q · filed 2026-08-06 | -$34.05M derived: sum of 3 quarters · filed 2026-08-06 | -$47.30M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$10.34M 10-Q · filed 2026-05-05 | -$21.75M derived: sum of 2 quarters · filed 2026-05-05 | -$35.00M derived: sum of 3 quarters · filed 2026-05-05 | -$47.35M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | -$11.41M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$24.66M derived: sum of 2 quarters · filed 2026-04-21 | -$37.01M derived: sum of 3 quarters · filed 2026-04-21 | -$47.91M DEF 14A · filed 2026-04-21 | -$47.91M 10-K · filed 2025-03-18 |
| 2024-09-30 | -$13.24M 10-Q · filed 2025-11-13 | -$25.59M derived: sum of 2 quarters · filed 2025-11-13 | -$36.50M 10-Q · filed 2025-11-13 | -$44.32M derived: sum of 4 quarters · filed 2026-04-21 | |
| 2024-06-30 | -$12.35M 10-Q · filed 2025-08-07 | -$23.25M 10-Q · filed 2025-08-07 | -$31.08M derived: sum of 3 quarters · filed 2026-04-21 | -$38.78M derived: sum of 4 quarters · filed 2026-04-21 | |
| 2024-03-31 | -$10.90M 10-Q · filed 2025-05-08 | -$18.73M derived: sum of 2 quarters · filed 2026-04-21 | -$26.43M derived: sum of 3 quarters · filed 2026-04-21 | -$33.57M derived: sum of 4 quarters · filed 2026-04-21 | |
| 2023-12-31 | -$7.83M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$15.52M derived: sum of 2 quarters · filed 2026-04-21 | -$22.67M derived: sum of 3 quarters · filed 2026-04-21 | -$29.07M DEF 14A · filed 2026-04-21 | -$29.07M 10-K · filed 2024-03-20 |
| 2023-09-30 | -$7.70M 10-Q · filed 2024-11-06 | -$14.84M derived: sum of 2 quarters · filed 2024-11-06 | -$21.24M 10-Q · filed 2024-11-06 | -$26.75M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$7.14M 10-Q · filed 2024-08-08 | -$13.55M 10-Q · filed 2024-08-08 | -$19.05M derived: sum of 3 quarters · filed 2024-08-08 | -$27.32M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$6.40M 10-Q · filed 2024-05-07 | -$11.91M derived: sum of 2 quarters · filed 2024-05-07 | -$20.17M derived: sum of 3 quarters · filed 2024-05-07 | -$28.22M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$13.77M derived: sum of 2 quarters · filed 2024-03-20 | -$21.82M derived: sum of 3 quarters · filed 2024-03-20 | -$29.15M 10-K · filed 2024-03-20 | |
| 2022-09-30 | -$8.27M 10-Q · filed 2023-11-09 | -$16.32M derived: sum of 2 quarters · filed 2023-11-09 | -$23.65M 10-Q · filed 2023-11-09 | -$32.17M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$8.05M 10-Q · filed 2023-08-10 | -$15.38M 10-Q · filed 2023-08-10 | -$23.90M derived: sum of 3 quarters · filed 2023-08-10 | -$31.16M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$7.33M 10-Q · filed 2023-05-11 | -$15.85M derived: sum of 2 quarters · filed 2023-05-11 | -$23.10M derived: sum of 3 quarters · filed 2023-05-11 | -$32.90M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$8.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$15.78M derived: sum of 2 quarters · filed 2023-03-16 | -$25.57M derived: sum of 3 quarters · filed 2023-03-16 | -$33.94M 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$7.25M 10-Q · filed 2022-11-10 | -$17.05M derived: sum of 2 quarters · filed 2022-11-10 | -$25.42M 10-Q · filed 2022-11-10 | -$34.94M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$9.79M 10-Q · filed 2022-08-11 | -$18.16M 10-Q · filed 2022-08-11 | -$27.69M derived: sum of 3 quarters · filed 2022-08-11 | -$35.07M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$8.37M 10-Q · filed 2022-05-12 | -$17.89M derived: sum of 2 quarters · filed 2022-05-12 | -$25.27M derived: sum of 3 quarters · filed 2022-05-12 | -$32.66M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$16.90M derived: sum of 2 quarters · filed 2022-03-17 | -$24.29M derived: sum of 3 quarters · filed 2022-03-17 | -$32.76M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$7.38M 10-Q · filed 2021-11-10 | -$14.76M derived: sum of 2 quarters · filed 2021-11-10 | -$23.23M 10-Q · filed 2021-11-10 | -$29.77M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$7.38M 10-Q · filed 2021-08-12 | -$15.86M 10-Q · filed 2021-08-12 | -$22.39M derived: sum of 3 quarters · filed 2021-08-12 | -$29.76M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$8.47M 10-Q · filed 2021-05-13 | -$15.01M derived: sum of 2 quarters · filed 2021-05-13 | -$22.38M derived: sum of 3 quarters · filed 2021-05-13 | -$29.72M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$13.90M derived: sum of 2 quarters · filed 2021-03-25 | -$21.25M derived: sum of 3 quarters · filed 2021-03-25 | -$26.05M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$7.37M 10-Q · filed 2020-11-12 | -$14.71M derived: sum of 2 quarters · filed 2020-11-12 | -$19.51M 10-Q · filed 2020-11-12 | -$25.50M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$7.35M 10-Q · filed 2020-08-13 | -$12.15M 10-Q · filed 2020-08-13 | -$18.13M derived: sum of 3 quarters · filed 2020-08-13 | -$23.78M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | -$4.80M 10-Q · filed 2020-05-07 | -$10.78M derived: sum of 2 quarters · filed 2020-05-07 | -$16.44M derived: sum of 3 quarters · filed 2020-05-07 | -$21.30M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$11.64M derived: sum of 2 quarters · filed 2020-03-16 | -$16.49M derived: sum of 3 quarters · filed 2020-03-16 | -$20.55M 10-K · filed 2020-03-16 | -$20.50M 10-Q · filed 2019-06-14 |
| 2018-09-30 | -$5.65M 10-Q · filed 2019-11-14 | -$10.51M derived: sum of 2 quarters · filed 2019-11-14 | -$14.56M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | -$4.86M 10-Q · filed 2019-08-12 | -$8.91M 10-Q · filed 2019-08-12 | |||
| 2018-03-31 | -$4.05M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |